Bilateral central retinal vein occlusion in non-Hodgkin lymphoma and the effects of intravitreal bevacizumab injection

Year 2012, Volume: 29 Issue: 1, 80 - 82, 17.04.2012

Ebru Cömert Yuksel Sullu

https://doi.org/10.5835/jecm.omu.29.01.021

Abstract

The purpose of this study is to report bilateral central retinal vein occlusion in a patient with non-Hodgkin lymphoma and the effects of intravitreal bevacizumab injection. This is a case report of a patient seen and treated in the ophthalmology department of Ondokuz Mayıs University Medical Faculty. Bilateral central retinal vein occlusion was observed in the patient because of hyperviscosity due to non-Hodgkin lymphoma which resulted in decreased visual acuity and increased macular thickness. Bilateral intravitreal bevacizumab injection increased best corrected visual acuity increased and reduced intraretinal, subretinal edema markedly. A hyperviscosity syndrome or inflammatory condition should be suspected when a patient, less than 50 years, has bilateral and simultaneous central retinal vein occlusion. Intravitreal bevacizumab injection is as an effective treatment for intraretinal and subretinal edema in central retinal vein occlusion secondary to non-Hodgkin lymphoma.

Keywords

Non-Hodgkin lymphoma, Central retinal vein occlusion, Intravitreal bevacizumab, Hyperviscosity syndrome

References

• Cheung, C.M., Tsaloumas, M.D., 2002. Acute myeloid leukaemia presenting as retinal vein occlusion and eyelid swelling. Eye.16, 202-203.
• Friedman, A.H., Marchesky, A., Odel, J.G., Gerber, M.A., Thung, S.N., 1980. Immunofluorescent studies of the eye in Waldenstrom's Macro- globulinemia. Arch. Ophthalmol. 98, 743-746.
• Grindle, C.F., Buskard, N.A., Newman, D.L., 1976. Hyperviscosity retinopathy, a scientific approach to therapy. Trans. Ophthal. Soc. 96, 216- 219.
• Hayreh, S.S., Zimmerman, M.B., Podhajsky, P., 2002. Hematologic abnormalities associated with various types of retinal vein occlusion. Graef- es Arch. Clin. Exp. Ophthalmol. 240, 180-196.
• Hayreh, S.S., 2003. Management of central retinal vein occlusion. Ophthalmologica. 217, 167-188.
• Iturralde, D., Spaide, R.F., Meyerle, C.B., Klancnik, J.M., Yannuzzi, L.A., Fisher, Y.L., Sorenson, J., Slakter, J.S., Freund, K.B., Cooney, M., Fine, H.F., 2006. Intravitreal bevasizumab treatment of macular edema in central retinal vein occlusion: A shorter-term study. Retina. 26, 279-284.
• Jaissle, G.B., Ziemssen, F., Petermeier, K., Szurman, P., Ladewig, M., Gelisken, F., Völker, M., Holz, F.G., Bartz-Schmidt, K.U., 2006. Bevaci- zumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmol. 103, 471-475.
• Kahook, M.Y., Schuman, J.S., Noecker, R.J., 2006. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthal. Surg. Las. Im. 37, 144-146.
• Priglinger, S.G., Wolf, A.H., Kreutzer, T.C., Kook, D., Hofer, A., Strauss, R.W., Alge, C.S., Kunze, C., Haritoglou, C., Kampik, A., 2007. Intra- vitreal bevacizumab injections for treatment of central retinal vein occlusion. Retina. 27, 1004-1012.
• Rosenfeld, P.J., Fung, A.E., Puliafito, C.A., 2005. Optical coherence tomography findings after an intravitreal injection of bevacizumab for macular edema from central retinal vein occlusion. Ophthal. Surg. Las. Im. 36, 336-339.
• Spalter, H.F., 1959. Abnormal serum proteins and retinal vein thrombosis. Arch. Ophthalmol. 52, 868-881.
• The Central Vein Occlusion Study Group, 1997. Natural history and clinical management of central retinal vein occlusion. Arch. Ophthalmol. 115, 486-491.
• Williamson, T.H., 1997. Central retinal vein occlusion: What’s the story? Br. J. Ophthalmol. 81, 698-704.